Bioequivalence Study of Cladribine 10 mg in Healthy Volunteers for Potential Use in Highly Active Relapsing Multiple Sclerosis

The primary objective of this study is to evaluate the **bioequivalence** of Cladribine 10 mg from two different pharmaceutical products. This is clinically relevant as Cladribine is intended for the treatment of adult patients with highly active relapsing **multiple sclerosis** (MS). Establishing bioequivalence ensures that the two formulations can be used interchangeably, providing flexibility in treatment options and potentially improving patient access to this medication. There are no secondary objectives specified for this trial.

The clinical trial involves **healthy volunteers** with no therapeutic indication in the current trial, although the intended indication is for the treatment of adult patients with highly active relapsing **multiple sclerosis** (MS). The study population consists exclusively of male participants, with an age range categorized as adults. The trial does not include a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population have not been disclosed, and no principal inclusion criteria have been specified. The trial is designed to assess the safety and efficacy of the intervention in a controlled environment.

The clinical trial is designed to evaluate the **bioequivalence** of Cladribine 10 mg from two different products. This study is a Phase 2 trial involving healthy volunteers, with no therapeutic indication in the current trial. The intended indication is for the treatment of adult patients with highly active relapsing **multiple sclerosis**. The trial is structured as a randomized, double-blind, controlled study to ensure the reliability and validity of the results. The estimated recruitment start date is February 15, 2024, with an anticipated end date of July 15, 2024, making the overall trial duration approximately five months.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status and collect necessary data. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the primary and secondary endpoints. The expected length of participant involvement is aligned with the trial duration, subject to adherence to the study protocol.

Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical standards and regulatory requirements to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, which typically focuses on assessing the efficacy of a treatment, as well as its side effects. The trial is scheduled to commence recruitment on February 15, 2024, with an estimated end date of July 15, 2024. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 2 trials generally involve measuring clinical outcomes to determine the treatment's effectiveness. The methods for measuring, collecting, and analyzing these parameters are not specified, but they often include validated scales, laboratory tests, and patient-reported outcomes. The trial's design and execution will adhere to standard clinical trial protocols to ensure the reliability and validity of the efficacy assessments.